Vascular endothelial growth factor concentration in the blod after treatment with aflibercept in the human eye.
Phase 1
- Conditions
- Exudative age-related macular degeneration (AMD)Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2014-000103-27-NO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with wet AMD
Central retinal thickness > 250 micrometers
Best corrected visual acuity 20/25-20/320
Age > 50 years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Macular edema of other ethiology
Bilateral disease
Intravitreal anti-VEGF treatment the last 3 months
Intraocular pressure > 30 mmHg
Active inflamation in the eye
Systemic steroid or anti-VEGF treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method